|
PTGFRN expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.68609570749823E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.46819999491399E-08 |
| Normal-vs-Stage2 |
3.958000E-03 |
| Normal-vs-Stage3 |
2.35039999996189E-06 |
| Normal-vs-Stage4 |
3.53060000002348E-06 |
| Stage1-vs-Stage2 |
3.105000E-01 |
| Stage1-vs-Stage3 |
6.685900E-02 |
| Stage1-vs-Stage4 |
7.177900E-02 |
| Stage2-vs-Stage3 |
2.377500E-02 |
| Stage2-vs-Stage4 |
3.217800E-02 |
| Stage3-vs-Stage4 |
8.410600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.96850313827213E-11 |
| Normal-vs-AfricanAmerican |
1.858860E-03 |
| Normal-vs-Asian |
5.7839000000004E-05 |
| Caucasian-vs-AfricanAmerican |
7.914200E-01 |
| Caucasian-vs-Asian |
7.237200E-01 |
| AfricanAmerican-vs-Asian |
6.034600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.13459999950827E-07 |
| Normal-vs-Female |
3.00869995584208E-10 |
| Male-vs-Female |
9.969000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.00800000013557E-07 |
| Normal-vs-Age(41-60Yrs) |
7.01179999618162E-08 |
| Normal-vs-Age(61-80Yrs) |
6.44399999999434E-05 |
| Normal-vs-Age(81-100Yrs) |
1.926570E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.434400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.532400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.793000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.984800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.208000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.999000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.412200E-01 |
| Classical-VS-Follicular |
6.45320019643236E-10 |
| Classical-VS-Other |
4.034600E-01 |
| Classical-VS-Normal |
3.60822483003176E-14 |
| Tall-VS-Follicular |
5.575100E-03 |
| Tall-VS-Other |
3.427200E-01 |
| Tall-VS-Normal |
2.881300E-03 |
| Follicular-VS-Other |
2.724400E-01 |
| Follicular-VS-Normal |
4.986600E-01 |
| Other-VS-Normal |
2.932600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.67510000000215E-05 |
| Normal-vs-N1 |
1.434050E-04 |
| N0-vs-N1 |
8.249800E-02 |
|
|
